MioMarin Pharmaceuticals has received full FDA approval for Vosoritide (VOXZOGO) to treat pediatric achondroplasia, converting its prior accelerated approval. This signifies a significant de-risking event for the drug and the company, confirming its long-term efficacy and safety.
MioMarin Pharmaceuticals (BMRN) announced that the FDA has granted full approval for its drug Vosoritide (VOXZOGO) for pediatric achondroplasia. This converts the prior accelerated approval, which was based on a surrogate endpoint, to a full approval based on long-term safety and efficacy data. This is a significant positive development for BMRN as it de-risks the drug's market position and confirms its clinical benefit, removing any uncertainty associated with the accelerated approval pathway. For traders, this solidifies BMRN's revenue stream from VOXZOGO and could lead to increased investor confidence and potentially a short-term positive stock movement, with long-term stability in this therapeutic area. The full approval also strengthens BMRN's competitive advantage in the achondroplasia market.